# AMICUS THERAPEUTICS, INC.

AMICUS THERAPEUTICS, INC. is a company headquartered in Princeton, NJ, United States.

## Company overview

- **Legal name:** AMICUS THERAPEUTICS, INC.
- **Former names in filing history:** AMICUS THERAPEUTICS INC (2002-07-25 to 2018-11-14)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Princeton, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001178879

## About

AMICUS THERAPEUTICS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001178879, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-02-20, it reported annual revenue of USD 634,210,000; net income of USD -27,110,000; total assets of USD 949,870,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $634.2M (USD 634,210,000)
- **Net income:** -$27.1M (USD -27,110,000)
- **Total assets:** $949.9M (USD 949,870,000)
- **Cash and equivalents:** $214.0M (USD 214,010,000)
- **Operating cash flow:** $33.1M (USD 33,145,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $528.3M (USD 528,295,000)
- **Net income:** -$56.1M (USD -56,106,000)
- **Total assets:** $785.0M (USD 785,033,000)
- **Cash and equivalents:** $213.8M (USD 213,752,000)
- **Operating cash flow:** -$33.9M (USD -33,891,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $399.4M (USD 399,356,000)
- **Net income:** -$151.6M (USD -151,584,000)
- **Total assets:** $777.9M (USD 777,880,000)
- **Cash and equivalents:** $247.0M (USD 246,994,000)
- **Operating cash flow:** -$69.1M (USD -69,091,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $329.2M (USD 329,233,000)
- **Net income:** -$236.6M (USD -236,568,000)
- **Total assets:** $724.2M (USD 724,167,000)
- **Cash and equivalents:** $148.8M (USD 148,813,000)
- **Operating cash flow:** -$166.6M (USD -166,575,000)

## Recent SEC filings

- Form 8-K — filed 2026-04-27 — period 2026-04-27 — 8-K
- Form 8-K — filed 2026-04-23 — period 2026-04-23 — 8-K
- Form 8-K — filed 2026-03-03 — period 2026-03-03 — FORM 8-K
- Form 10-K — filed 2026-02-20 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-02-20 — period 2026-02-20 — FORM 8-K
- Form 8-K — filed 2026-01-26 — period 2026-01-26 — 8-K
- Form 8-K — filed 2025-12-19 — period 2025-12-19 — 8-K
- Form 10-Q — filed 2025-11-04 — period 2025-09-30 — 10-Q
- Form 8-K — filed 2025-11-04 — period 2025-11-04 — FORM 8-K
- Form 10-Q — filed 2025-07-31 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-07-31 — period 2025-07-31 — FORM 8-K
- Form 8-K — filed 2025-06-05 — period 2025-06-05 — FORM 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/amicus-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology